Emergent BioSolutions | EBS - Trade Debtors


Emergent BioSolutions reported $290.1M in Trade Debtors for its fiscal quarter ending in June of 2023.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Akebia Therapeutics USD 61.54M 27.17M Mar/2025
ALKERMES USD 334.02M 21.08M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amarin USD 127.31M 8.18M Sep/2025
ANI Pharmaceuticals USD 281.08M 28.46M Dec/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Coherus Biosciences USD 62.44M 59.9M Mar/2025
Emergent BioSolutions USD 290.1M 134.2M Jun/2023
Exact Sciences USD 306.05M 47.28M Sep/2025
Exelixis USD 286.92M 24.38M Dec/2025
Glaxosmithkline GBP 11.16B 3.46B Sep/2025
Heron Therapeutics USD 67.04M 6.9M Sep/2024
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Lexicon Pharmaceuticals USD 2.62M 1.09M Jun/2024
Lonza CHF 1.78B 55M Dec/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 184M 862M Dec/2025
Myriad Genetics USD 118M 19M Sep/2025
Nektar Therapeutics USD 0 2.9M Sep/2024
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Pacira USD 124.07M 8.8M Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Sanofi EUR 397M 100M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
United Therapeutics USD 350.2M 52.5M Dec/2025
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Xoma USD 14.78M 4.96M Jun/2024